Fig. 1From: Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphomaIbrutinib is the first-in-class BTK inhibitor, followed by second-generation and noncovalent BTK inhibitors. BCL2 inhibitor venetoclax, anti-CD20 mAbs, chemoimmunotherapy, and CAR-T therapy have been combined with BTK inhibitors for fixed-duration treatment. BTKi, BTK inhibitors; CAR-T, chimeric antigen receptor T-cell; FCR, fludarabine, cyclophosphamide and rituximab; FCG, fludarabine, cyclophosphamide and obinutuzumab; G, obinutuzumab; mAbs, monoclonal antibodies; R, rituximabBack to article page